Artificial intelligence (AI) can accelerate drug development, reduce costs, and improve treatment efficacy, but faces challenges like data quality and regulatory hurdles. Over 900 FDA-approved ...
Bruker's Acquifer Imaging Machine (IM) is a fully automated widefield microscope with both brightfield and fluorescence imaging capabilities. It is best suited for high-content screening (HCS) and ...
Google Research and Google DeepMind recently released a paper announcing the creation of a new LLM for drug discovery and therapeutic development dubbed Tx-LLM, fine-tuned from PaLM-2. Tx-LLM utilizes ...
Generative AI based on Large Language Models (LLMs), the technology behind popular tools like ChatGPT and Google Gemini, is revolutionizing various industries, including the world of drug discovery.
Regina Barzilay is a School of Engineering Distinguished Professor of AI & Health in the department of computer science and the AI faculty lead at MIT Jameel Clinic. She develops machine learning ...
New approach methodologies (NAMs) aim to address the limitations of animal models by assessing drug efficacy and safety in a more ethical, human-relevant way. The term ‘NAMs’ encompasses several ...
Avner Schlessinger, PhD, right, working with his lab researchers at Mount Sinai AI Small Molecule Drug Discovery Center in New York City. [Mount Sinai] Most breakthrough discoveries are made based on ...
In 2025, Generative AI will prove transformational for drug discovery in the healthcare industry. With the use of deep learning and advanced algorithms, generative AI can promote acceleration in the ...
Traditionally, developing a new drug takes many years and requires a massive financial investment, often involving significant risk and a high likelihood of failure. AI models trained on extensive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback